Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pliant Therapeutics Inc PLRX

Healthcare
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avß6 and avß1 integrins that is in development in the lead indications for the treatment of idiopathic... see more

Recent & Breaking News (NDAQ:PLRX)

Pliant Therapeutics to Participate in Upcoming Investor Events

GlobeNewswire April 2, 2024

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

GlobeNewswire March 27, 2024

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire March 12, 2024

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

GlobeNewswire February 27, 2024

Pliant Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 26, 2024

Pliant Therapeutics to Participate in Upcoming Investor Events

GlobeNewswire February 7, 2024

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

GlobeNewswire February 4, 2024

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

GlobeNewswire November 13, 2023

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

Pliant Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 8, 2023

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

GlobeNewswire November 6, 2023

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire October 31, 2023

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

GlobeNewswire October 19, 2023

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

GlobeNewswire October 16, 2023

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

GlobeNewswire September 26, 2023

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

GlobeNewswire September 25, 2023

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

GlobeNewswire September 15, 2023

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

GlobeNewswire September 11, 2023

Pliant Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 30, 2023